[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596083":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":11,"centralContacts":64,"locations":76,"responsibleParty":89,"collaborators":11,"id":93,"slug":11,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":11,"eligibilityCriteria":98,"healthyVolunteers":99,"sex":100,"minAge":101,"maxAge":11,"enrollmentInfo":102,"targetDuration":11,"studyType":105,"phases":106,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":115,"whyStopped":11,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"Rehman Medical Institute - RMI","OTHER",[8,16,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"First-Line Therapy with Omeprazole","EXPERIMENTAL",null,[13,14,15],"Drug: Clarithromycin 500 mg","Drug: Amoxicillin 1 g","Drug: Omeprazole 40 mg",{"label":17,"type":10,"description":11,"interventionNames":18},"First-Line Therapy with Vonoprazan",[13,14,19],"Drug: Vonoprazan 20 mg",{"label":21,"type":10,"description":11,"interventionNames":22},"Second-Line Therapy with Omeprazole",[23,14,15],"Drug: Levofloxacin 500 mg",{"label":25,"type":10,"description":26,"interventionNames":27},"Second-Line Therapy with Vonoprazan","Participants receiving second-line therapy (levofloxacin + amoxicillin) with vonoprazan as the acid suppressant.",[23,14,19],[29,34,38,41,43,46,50,54,56,58,60,62],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":11},"DRUG","Clarithromycin 500 mg","Clarithromycin 500 mg orally twice daily for 14 days",[9],{"type":30,"name":35,"description":36,"armGroupLabels":37,"otherNames":11},"Amoxicillin 1 g","Omeprazole 40 mg orally twice daily for 14 days, then 40 mg once daily for 4 weeks",[9],{"type":30,"name":39,"description":36,"armGroupLabels":40,"otherNames":11},"Omeprazole 40 mg",[9],{"type":30,"name":31,"description":32,"armGroupLabels":42,"otherNames":11},[17],{"type":30,"name":35,"description":44,"armGroupLabels":45,"otherNames":11},"Amoxicillin 1 g orally twice daily for 14 days",[17],{"type":30,"name":47,"description":48,"armGroupLabels":49,"otherNames":11},"Vonoprazan 20 mg","Vonoprazan 20 mg orally twice daily for 14 days, then 20 mg once daily for 4 weeks",[17],{"type":30,"name":51,"description":52,"armGroupLabels":53,"otherNames":11},"Levofloxacin 500 mg","Levofloxacin 500 mg orally once daily for 14 days",[21],{"type":30,"name":35,"description":44,"armGroupLabels":55,"otherNames":11},[21],{"type":30,"name":39,"description":36,"armGroupLabels":57,"otherNames":11},[21],{"type":30,"name":51,"description":52,"armGroupLabels":59,"otherNames":11},[25],{"type":30,"name":35,"description":44,"armGroupLabels":61,"otherNames":11},[25],{"type":30,"name":47,"description":48,"armGroupLabels":63,"otherNames":11},[25],[65,71],{"name":66,"role":67,"phone":68,"phoneExt":69,"email":70},"Taimur khan, FCPS","CONTACT","03305485960","3638","taimur.khan@rmi.edu.pk",{"name":72,"role":67,"phone":73,"phoneExt":74,"email":75},"Naseer Ahmed, Associate professor","09291583000","4743","dr.naseerahmed99@gmail.com",[77],{"facility":78,"status":11,"city":79,"state":80,"zip":81,"country":82,"cosmosGeoPoint":83,"geoPoint":88,"contacts":11},"Rehman Medical Institue","Peshawar","K","092","Pakistan",{"type":84,"coordinates":85},"Point",[86,87],71.57849,34.008,{"lat":87,"lon":86},{"type":90,"investigatorFullName":91,"investigatorTitle":92,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Wajeeha Qayyum","Consultant\u002FAssistant Professor Medicine","100596083",false,"NCT07040839","Comparison of Omeprazole vs Vonoprazon in Treatment of H Pylori Infection","Comparative Efficacy of Omeprazole and Vonoprazan in the Treatment of Helicobacter Pylori Infection","Inclusion Criteria:\n\n* All patients who tested positive on stool antigen\n\nExclusion Criteria:\n\n* patients under 12 years old.\n* Patients who have penicillin allergy.\n* Patients who have underlying dysrhythmia forbidding the use of macrolide -. Patient who have hypersensitivity to any of these antibiotics or proton pump inhibitors.",true,"ALL","12 Years",{"count":103,"type":104},128,"ESTIMATED","INTERVENTIONAL",[107],"PHASE4","Current studies have primarily focused on comparing the advantages and disadvantages of P-CAB and PPI drugs, with little comparison between different P-CAB drugs or between regimens with varying drug combinations and treatment durations.\n\nThis study aims to evaluate the clinical effectiveness of vonoprazan-based H. pylori eradication therapy and compare it to that of conventional PPI based therapy in clinical practice.",[110],"H Pylori",[112,113,114],"omeprazole","vonoprazon","proton pump inhibitors","NOT_YET_RECRUITING","2025-06-26",{"date":118,"type":119},"2025-06-27","ACTUAL",{"date":121,"type":104},"2025-07",{"date":123,"type":104},"2026-02",{"name":5,"class":6},1]